Skip to main content

Table 1 Characteristics of the development and validation datasets

From: Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort

Characteristic Development cohort (n = 117) Validation cohort (n = 144) p-value
n (%) n (%)
Sex    0.1
 Male 79 (67.5) 83 (57.6)  
 Female 38 (32.5) 61 (42.4)  
Age (years)    0.31
 Median (range) 73 (34–90) 74 (45–91)  
ECOG performance status    0.025
 0 55 (47.0) 44 (30.6)  
 1 35 (29.9) 61 (42.4)  
 ≥ 2 27 (23.1) 36 (25.0)  
 Unknown 0 (0) 3 (2.1)  
SCS    0.16
 0–9 77 (65.8) 104 (72.2)  
 10–20 40 (34.2) 37 (35.6)  
 Unknown 0 (0) 3 (2.1)  
Smoking status    0.53
 Current 38 (32.5) 37 (25.7)  
 Past 71 (60.7) 93 (64.6)  
 Never 7 (6.0) 10 (6.9)  
 Unknown 1 (0.9) 4 (2.8)  
Pack years smoked    0.7
 Median (range) 40 (0–150) 40 (0–150)  
 Unknown 7 (6.0) 7 (4.9)  
Weight loss (%)     < 0.001
 None 57 (48.7) 41 (28.5)  
 ≤ 10 29 (24.8) 51 (35.4)  
 > 10 25 (21.4) 7 (4.9)  
 Unknown 6 (5.1) 45 (31.3)  
FEV1 (%)    0.19
 Median (range) 68 (25–121) 68 (30–133)  
 Unknown 16 (13.7) 36 (25.0)  
DLCO (%)    0.5
 Median (range) 60 (28–115) 58 (28–134)  
 Unknown 24 (20.5) 84 (58.3)  
Overall stage    0.016
 I 34 (29.1) 62 (43.1)  
 II 22 (18.8) 13 (9.0)  
 III 61 (52.1) 69 (47.9)  
T stage    0.086
 T1 31 (26.5) 54 (37.5)  
 T2 38 (32.5) 52 (36.1)  
 T3 33 (28.2) 25 (17.4)  
 T4 14 (12.0) 13 (9.0)  
 Unknown 1 (0.9) 0 (0)  
N stage    0.065
 N0 56 (47.9) 79 (54.9)  
 N1 14 (12.0) 5 (3.5)  
 N2 31 (26.5) 42 (29.2)  
 N3 16 (13.7) 18 (12.5)  
Histological diagnosis    0.034
 Squamous cell carcinoma 64 (54.7) 24 (16.7)  
 Adenocarcinoma 37 (31.6) 45 (31.3)  
 Other 16 (13.7) 69 (47.9)  
Tumour grade    0.11
 < 3 36 (30.8) 24 (16.7)  
 3 39 (33.3) 45 (31.3)  
 Unknown 42 (35.9) 75 (52.1)  
Tumour laterality    0.23
 Left 48 (41.0) 71 (49.3)  
 Right 67 (57.3) 73 (50.7)  
 Unknown 2 (1.7) 0 (0)  
Tumour lobe    0.76
 Upper 71 (60.7) 86 (59.7)  
 Middle/lower 44 (37.6) 57 (39.6)  
 Unknown 2 (1.7) 1 (0.7)  
GTV (cc)    0.32
 Median (range) 49.8 (0.7–1039.0) 23 (1.7–1065.0)  
 Unknown 26 (22.2) 29 (20.1)  
Mutation status    0.28
 EGFR positive 4 (3.4) 8 (5.6)  
 ALK positive 1 (0.9) 2 (1.4)  
 None 36 (30.8) 30 (20.8)  
 Unknown 76 (65.0) 104 (72.2)  
PD-L1 status (%)    0.45
 < 1 4 (3.4) 2 (1.4)  
 1–49 8 (6.8) 4 (2.8)  
 ≥ 50 5 (4.3) 2 (1.4)  
 Unknown 100 (85.5) 136 (94.4)  
Radiotherapy technique     < 0.001
 Conformal 15 (12.8) 80 (55.6)  
 IMRT 80 (68.4) 24 (16.7)  
 VMAT 22 (18.8) 39 (27.1)  
 Unknown 0 (0) 1 (0.7)  
Radiotherapy treatment duration (days)    0.37
 Median (range) 26 (1–47) 22 (1–48)  
EQD2 (Gy)    0.12
 Median (range) 60 (12–126) 60 (6.3–88)  
Chemotherapy use    0.18
 Chemotherapy 45 (38.5) 44 (30.6)  
 No chemotherapy 72 (61.5) 100 (69.4)  
Survival time (months)    0.011
 Median (range) 17 (1–44) 22 (0–46)  
2-year status    0.92
 Alive 56 (47.9) 68 (47.2)  
 Dead 61 (52.1) 76 (52.8)  
  1. ECOG = Eastern Cooperative Oncology Group; SCS = Simplified Comorbidity Score; FEV1 = forced expiratory volume in 1 s; DLCO = diffusing capacity of the lung for carbon monoxide; GTV = gross tumour volume; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase, PD-L1 = programmed death-ligand 1; IMRT = intensity-modulated radiotherapy; VMAT = volumetric modulated arc therapy; EQD2 = equivalent dose in 2 Gy fractions
  2. Comparison of development and validation cohort